Evaluation of Selective Survival and Sex/Gender Differences in Dementia Incidence Using a Simulation Model.


Journal

JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235

Informations de publication

Date de publication:
01 03 2021
Historique:
entrez: 9 3 2021
pubmed: 10 3 2021
medline: 22 6 2021
Statut: epublish

Résumé

Dementia research is susceptible to bias arising from selective survival, a process that results in individuals with certain characteristics disproportionately surviving to old age. Spurious associations between risk factors and dementia may be induced when factors associated with longer survival also influence dementia incidence. To assess the role of selective survival in explaining reported sex/gender differences in dementia incidence. This decision analytical model used a simulated cohort of US participants aged 50 years and without dementia at baseline followed up for incident dementia through age 95 years. Selective survival was induced by a selection characteristic (eg, childhood social disadvantage or Alzheimer genetic risk) that influenced both mortality and dementia incidence at varying magnitudes. Data analysis was performed from April 2018 to May 2020. Sex/gender, conceptualized as the combination of biological sex and social consequences of gender. Dementia incidence rate ratios (IRRs) for women compared with men. In all simulations, it was assumed that there would be no true effect of sex/gender on dementia incidence; all observed sex/gender differences were due to selective survival. At baseline, the simulation included 100 000 participants aged 50 years (51 000 [51%] women, mirroring the 1919-1921 US birth cohort of non-Latino White individuals at age 50 years); distributions of the selection characteristic were standard normal (mean [SD], 0.0 [1.0]). Observed sex/gender differences in dementia incidence in individuals aged 85 years or older ranged from insignificant (IRR, 1.00; 95% CI, 0.91-1.11) to consistent with sex/gender differences (20% higher risk for women [IRR, 1.20; 95% CI, 1.08-1.32]) reported in an extant study. Simulations in which bias was large enough to explain prior findings required moderate to large differential effects of selective survival (eg, hazard ratio for selection characteristic on mortality at least 2.0 among men, no effect among women). These results suggest that selective survival may contribute to observed sex/gender differences in dementia incidence but do not preclude potential contributions of sex/gender-specific mechanisms. Further research on plausibility of selection characteristics with outcomes of the magnitude required for selective survival to explain sex/gender differences in dementia incidence and sex/gender-specific mechanisms represent an opportunity to understand prevention and treatment of dementia.

Identifiants

pubmed: 33687445
pii: 2777217
doi: 10.1001/jamanetworkopen.2021.1001
pmc: PMC7944377
doi:

Types de publication

Comparative Study Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

e211001

Subventions

Organisme : NIA NIH HHS
ID : R21 AG059941
Pays : United States
Organisme : NIA NIH HHS
ID : RF1 AG050782
Pays : United States
Organisme : NIA NIH HHS
ID : R00 AG053410
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG059716
Pays : United States
Organisme : NIA NIH HHS
ID : R21 AG055361
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG069128
Pays : United States
Organisme : NICHD NIH HHS
ID : P2C HD041022
Pays : United States
Organisme : NIA NIH HHS
ID : K01 AG049164
Pays : United States
Organisme : NIA NIH HHS
ID : R13 AG064971
Pays : United States

Références

Neurology. 2000;54(11 Suppl 5):S10-5
pubmed: 10854355
Neurology. 2013 May 7;80(19):1778-83
pubmed: 23390181
Eur J Neurol. 2020 Jun;27(6):928-943
pubmed: 32056347
Epidemiology. 2018 Jul;29(4):525-532
pubmed: 29621058
Am J Epidemiol. 2016 Sep 1;184(5):378-87
pubmed: 27578690
Neurobiol Aging. 2019 Jun;78:178-185
pubmed: 30947113
Alzheimers Dement. 2016 Feb;12(2):170-183
pubmed: 26519786
PLoS One. 2013 May 20;8(5):e63347
pubmed: 23700418
BMJ Glob Health. 2017 Mar 27;2(2):e000298
pubmed: 28589033
Ann Neurol. 2010 Jan;67(1):114-21
pubmed: 20186856
Brain Imaging Behav. 2014 Jun;8(2):262-73
pubmed: 24293121
Alzheimers Dement (Amst). 2016;2:1-11
pubmed: 26949733
J Am Geriatr Soc. 2019 Sep;67(9):1970-1976
pubmed: 31211407
Neurology. 2001 Jan 9;56(1):49-56
pubmed: 11148235
Alzheimers Dement. 2018 Sep;14(9):1193-1203
pubmed: 29803541
Ann Epidemiol. 2003 Jul;13(6):472-8
pubmed: 12875807
Brain. 2019 Sep 1;142(9):2581-2589
pubmed: 31497858
J Alzheimers Dis. 2003 Oct;5(5):349-55
pubmed: 14646025
Am J Epidemiol. 1998 Mar 15;147(6):574-80
pubmed: 9521184
Alzheimers Dement. 2016 Mar;12(3):216-24
pubmed: 26874595
Am J Public Health. 2015 Feb;105(2):408-13
pubmed: 25033130
Alzheimers Dement. 2015 Sep;11(9):1098-109
pubmed: 26397878
Neurology. 2002 Jan 22;58(2):209-18
pubmed: 11805246
Alzheimers Dement. 2019 Apr;15(4):497-505
pubmed: 30797730
Sci Transl Med. 2020 Aug 26;12(558):
pubmed: 32848093
Clin Epidemiol. 2014 Jan 08;6:37-48
pubmed: 24470773
JAMA Neurol. 2017 Oct 1;74(10):1246-1254
pubmed: 28783817
Am J Epidemiol. 2019 Jul 1;188(7):1224-1227
pubmed: 30824902
Curr Genet Med Rep. 2019 Mar;7(1):13-21
pubmed: 31360619
Arch Neurol. 2002 Nov;59(11):1737-46
pubmed: 12433261
JAMA Neurol. 2019 May 1;76(5):542-551
pubmed: 30715078
Alzheimers Dement. 2017 Feb;13(2):103-110
pubmed: 28108119
Alzheimers Dement. 2019 Dec;15(12):1516-1523
pubmed: 31606366
Alzheimers Dement. 2018 Sep;14(9):1101-1103
pubmed: 30196887
J Neurol Neurosurg Psychiatry. 1999 Feb;66(2):177-83
pubmed: 10071096
Neuroepidemiology. 2005;25(4):181-91
pubmed: 16103729
Int J Epidemiol. 2018 Oct 1;47(5):1507-1517
pubmed: 30010793

Auteurs

Crystal Shaw (C)

Fielding School of Public Health, Department of Epidemiology, University of California, Los Angeles.
Fielding School of Public Health, Department of Biostatistics, University of California, Los Angeles.

Eleanor Hayes-Larson (E)

Fielding School of Public Health, Department of Epidemiology, University of California, Los Angeles.

M Maria Glymour (MM)

Department of Epidemiology and Biostatistics, University of California, San Francisco.

Carole Dufouil (C)

Centre Inserm U1219, d'Epidémiologie et de Développement, Bordeaux School of Public Health, Institut de Santé Publique Université de Bordeaux, Bordeaux, France.
Pole de sante publique, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.

Timothy J Hohman (TJ)

Vanderbilt Memory and Alzheimer's Center, Vanderbilt University Medical Center, Nashville, Tennessee.
Vanderbilt Genetics Institute, Vanderbilt University Medical Center, Nashville, Tennessee.

Rachel A Whitmer (RA)

Alzheimer's Disease Research Center, University of California, Davis.
Department of Public Health Sciences, University of California, Davis.

Lindsay C Kobayashi (LC)

Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor.

Ron Brookmeyer (R)

Fielding School of Public Health, Department of Biostatistics, University of California, Los Angeles.

Elizabeth Rose Mayeda (ER)

Fielding School of Public Health, Department of Epidemiology, University of California, Los Angeles.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH